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Abstract
Transposable elements (TEs) are mobile genetic sequences that are able to move in the
genome from one location to another. TEs were first regarded as junk or selfish DNA, as
they comprise the largest molecular class within most metazoan genomes having no
genomic function. It was necessary to wait until whole genome sequencing to provide
new insights about the origin, diversity, and impact of TEs on the genome function. Thus,
due to advances in molecular technology, TEs have been shown to create new regulato‐
ry sequence networks. Although nowadays most TEs present in the human genome are
silenced, particularly DNA transposons, it does not mean that these sequences are dead.
In this review, we detail how DNA transposons could be emphasized to create a new tool
for gene correction. DNA-based transposon vectors are derived from three models:
Sleeping Beauty, piggyBac, and Tol2, which all work via a “cut-and-paste” mechanism
where transposase enzyme is alone able to catalyze the transposition process, which means
integrating the genes of interest in chromosomal DNA. Limitations and improvements
of the systems are discussed, particularly the latest way to target a specific integration
site, showing that the DNA transposon-derived system and its engineering, are powerful
tools for gene correction.
Keywords: transposon, piggyBac, Sleeping Beauty, gene transfer, Molecular engineer‐
ing
1. Introduction
1.1. Transposable elements (TEs) in the genome: a brief history from their discovery to their
biotechnological use in gene transfer
TEs, also described as “jumping genes,” were first discovered in maize by Barbara McClin‐
tock in the 1940s. TEs are discrete pieces of DNA that are able to move from one site to another
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
within one genome. This new concept, which suggested that the genome was not a final design
but was rather able to evolve, to rearrange, was first met with criticism. However, a large body
of  evidence  has  accumulated over  the  last  60  years  not  only  on  the  categorization  and
classification of TEs [1] but also on the understanding of their mechanisms. The ability to
accurately identify and classify these sequences is critical to understand their impact on host
genomes.  Pioneers  such  as  Finnegan  [2]  classified  TEs  into  two  classes  based  on  their
mechanism of transposition (Figure 1). Class I elements transpose by reverse transcription
using an RNA intermediate: they are named retrotransposons. Three kinds of enzyme, RNA
polymerase,  reverse transcriptase,  and integrase,  are used for transposition.  Class II  ele‐
ments directly transpose from DNA to DNA: they are named DNA transposons and just one
enzyme, the transposase, is needed.
Figure 1. Classes I and II transposable elements (TEs, in green). Class I transposon or RNA transposon: three enzymes
are necessary to transpose (1: RNA polymerase, 2: reverse transcriptase and 3: integrase). This mechanism is called
“copy-and-paste” and gives rise to two identical copies ; one in the donor site and one in the target site. Class II trans‐
poson or DNA transposon: only one enzyme, the transposase, catalyzes the excision and the integration processes. The
mechanism is named “cut-and-paste” and translocates the TE element in the target site leaving a free TE donor site.
Inverted terminal repeats (ITRs) are drawned in red.
Piégu et al. [1] clearly detailed the necessity to update this classification. TEs are widely
distributed in prokaryotic and eukaryotic genomes and represent a variable fraction account‐
ing for 8% in chicken to 85% in maize. After an initial phase of sudden episodic bursts, the
invasion step, TEs proliferate and accumulate mutations. Finally, transposition is tolerated by
the genome at a reduced rate. Some TE insertions contribute with new genes, exons, or
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regulator regions. This has been called the exaptation [3] and domestication [4] processes.
However, for a significant amount of time, TEs were primarily considered as “junk or selfish
DNA” that played no significant role in genome evolution [5]. The modern-day view of TEs
is that they can generate genomic instability and reconfigure gene expression networks in both
germline and somatic cells. This comprehensive view came with significant advances in
sequencing technologies and the development of bioinformatics tools. One of the most
unexpected insights is that almost half of our DNA is derived from TEs and 75% of our genome
is transcribed (ENCODE project [6]). Therefore, as an integral part of the genome, the dynamic
presence of TEs will be a major force to naturally reshape genomes. Several researchers have
found examples of concordant timing between bursts of transposition or massive extinction
and speciation events. For example, Lynch et al. [7] noticed how transposons transformed the
uterine regulatory landscape during the evolution of mammalian pregnancy and Britten [8]
reviewed the importance of Alu inserts on brain growth. Thus, TEs are “spam” coming from
the dark ages and nowadays a small proportion of retroelements (<0.05%) remains able to
transpose in humans [9]. However, no evidence of DNA transposon families was found active
in the human genome during the later phase of the primate Radiation, 37 million years ago
[10]. The last active DNA transposons were from the hAT superfamily, the Tc1/mariner, and
the piggyBac families. This suggests that three sources of transposase were silenced at the same
evolutionary period. As previously discussed, although transposons have been silenced, it
does not mean that they are dead sequences for the genome and they constitute new regulatory
networks.
Thus, DNA TEs present distinguishing features, making them attractive as gene transfer tools.
Indeed, they are not infectious, as they are able to mobilize DNA in a single genome and are
ubiquitous. From the natural architecture of DNA transposons, a secure and easy system has
been designed (Figure 2).
Figure 2. From natural transposon to engineered pseudo-transposon. a) In the natural transposon, the transposase ORF
(green rectangle) is delineated by the two ITRs (red arrows). b) In engineered pseudo-transposon, the transposase ORF
is replaced by the cassette of the gene of interest. Transposase should therefore be delivered in parallel either in DNA,
mRNA or protein form.
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Briefly, the transposon is naturally delineated by two inverted terminal repeats (ITRs) framing
the unique transposase open reading frame (ORF). The transposase recognizes the ITRs and
catalyzes the excision and integration processes (Figure 1). After engineering, the transposase
ORF is replaced by the gene of interest cassette and the enzyme is brought independently
(Figure 2). The transposase is then able to integrate any gene of interest, without cross-
mobilization between transposon families, as the ITR sequences are highly specific for each
transposase. From this global conception of the transposon tool, numerous technological
aspects have been explored, finally resulting in an attractive gene integrative system to modify
the human genome.
2. Transposon-based strategies
Various transposon-based strategies are available to obtain efficient transgene integration
while maintaining safety and cell integrity. First, it depends on the transposase used to govern
the efficacy of the integration process. Second, it depends on the way the transposase and the
transgene would be delivered. Some use only one plasmid carrying the transposase expression
cassette and the transgene construct. Other strategies rely on using one helper molecule
carrying the transposase under gene, mRNA, or protein form and one donor plasmid that
brings the gene of interest delineated by two ITRs.
2.1. Different types of transposase
For genome engineering, two strategies have been developed: find a transposase in any other
species that works in humans or create a new one considering that nowadays no DNA
transposons are found active in mammalian genomes. After the identification of efficient
transposases for gene correction, their activities have been dissected and optimized.
2.1.1. The three musketeers
For decades, three main transposases have been developed with the aim of gene correction:
Sleeping Beauty (SB), piggyBac (PB) and Tol2. In 1997, the SB transposase was artificially
reconstructed from partial ancestral copies of a transposase gene identified in salmonid Salmo
sp. [11]. The Tol2 and piggyBac transposases have been found to be active in their natural host.
The piggyBac transposase was isolated from the cabbage looper moth Trichoplusia ni, and the
developed tool is active in human and mice cells [12]. Tol2 was isolated from the Japanese
medaka fish Oryzias latipes [13]. It is active in vertebrate cells including zebrafish, chicken,
mouse and human.
Following their discovery, various optimizations were carried out to increase their transposi‐
tion efficiency. The development of the SB100x transposase [14], characterized by a 100-fold
greater efficacy than the natural SB, stands as an important step of transposase optimization.
Comparatively, in 2011, a hyperactive piggyBac transposase was found with 17- and 9-fold
increases in excision and integration, respectively [15], and a codon-optimized PB (mPB) was
also developed [16]. Following this, the efficacy of this hyperactive PB (hyPb or 7PB) was
compared to SB100x by luciferase in vivo expression. Mice injected with m7pB had 10 times
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greater luciferase expression than those injected with SB100x [17]. Currently, no optimization
studies have been carried out On the Tol2 enzyme since it is higly sensitive to molecular
engineering [1].
2.1.2. Transposases confer specific properties to the system
Naturally, each transposase governs the integration of the pseudo-transposon using their own
target site. The integration site for the SB transposon is TA, whereas it is TTAA for the PB
transposon and 8-bp target duplication for the Tol2 transposon. After integration, these target
sites are duplicates on either side of the newly integrated pseudo-transposon. Besides this
specific transposition signature, the SB, PB, and Tol2 transposases confer specific properties
to the system, such as cargo size capacity, overproduction inhibition (OPI), and reversibility
with or without footprint.
2.1.2.1. Cargo size capacity
The distance between ITRs delineates the cassette transgene and defines the cargo size
capacity. The more this distance is important, the less the transposase is efficient for excision
and integration. However, the constant optimization of the enzymes improved considerably
the efficacy of the system.
For now, the SB transposase initially allowed the transposition of only 10-kb transposon [18].
Beyond this size, the transposition rate is abolished. In 2014, Turchiano et al. [19] suggested to
change its configuration, permitting the use of SB transposon until 18 kb but with a reduced
efficiency. To date, the PB transposon offers the higher cargo size capacity with a natural high
activity with 14.3-kb transgenes [12]. The hyPB transposase allows transposition of transgenes
up to 100 kb in mouse ES cells [20]. In contrast, Tol2 does not show decrease of transposition
efficacy until 10-kb transposon [21], and its activity has been proven until 66 kb [22]. However,
few studies have directly compared the transposition efficacy of the transposases in an
identical system [23].
Raising cargo size capacity opens new perspectives in gene correction. For example, in
muscular dystrophy, disease is induced by the dystrophin mutation. Adding the full-length
cDNA of the dystrophin, 11-kb length, has been proven complicated using viral gene transfer.
Recently, the full-length dystrophin cDNA has been successfully integrated in mesangioblasts
from a dystrophic dog model using the PB transposon tool [24].
2.1.2.2. Overproduction inhibition
As previously discussed, the transposase is brought independently to the pseudo-transposon,
and the ratio between the enzyme and the pseudo-transposon turns out to be important to
establish. On the one hand, transposases act by creating double-stranded breaks so the amount
of transposase used must be the lowest possible to avoid genotoxicity. On the other hand, it is
necessary to have enough transposase for having high transposition rate. Unexpectedly,
increasing the amount of transposase does not result in more transposition activity. Indeed,
even if at low level the transposition rate increases with the amount of transposase until a
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maximum value, it is abolished above. This phenomenon is called OPI and depends on the
studied model and the type of transposase [25]. In other cases, the transposition rate is
saturated, without decrease, and a plateau is observed. The OPI has been well documented
for a long time concerning the SB transposase [26]. However, concerning the PB and Tol2
transposases, the OPI is not as clear. For example, the PB transposase showed an OPI phe‐
nomenon in HeLa cells [16], but a stabilization of the activity was demonstrated in HEK293
[27] or mouse ES cells [28]. Similarly, for its Tol2 transposase, OPI or stabilization has been
observed [16,21]. The molecular mechanism of this phenomenon is not still clearly established.
Numerous hypotheses have been subjected and reviewed in Ref. [25].
2.1.2.3. Integration is reversible
In some conditions, the desired integration needs to be reversed. The transposase could then
been readded with the aim of excising the pseudo-transposon from its chromosomal location.
The excision of SB pseudo-transposons drives a footprint signature creating a 5-bp insertion
[29]. Tol2 transposase excisions have been less investigated, but they could leave a short
insertion or deletion [30]. In contrast, PB transposases have the particularity to carry out this
excision without leaving a footprint in the genomic sequence. This property has been exten‐
sively exploited in induced pluripotent stem cells (iPSC) generation [31–33]. For more security,
it is possible to use an engineered PB transposase in which the integration efficacy is abolished
while conserving its excision property [34].
2.2. Design of the coupled pseudo-transposon/transposase architecture
Besides the intrinsic particularities of the transposases, the cellular delivery system is crucial.
In a first system, called “cis” configuration, only one plasmid carries both the transposase and
the gene of interest. The second way, termed “trans” configuration, is based on the principle
of separately bringing the gene of interest on one plasmid, “donor” plasmid, and the trans‐
posase under a “helper” plasmid or mRNA or protein form.
2.2.1. “Cis” versus “trans” configurations
In the cis configuration, only one plasmid needs to be prepared. This confers easier manipu‐
lation and high efficacy, but three drawbacks need to be overcome. First, the pseudo-transpo‐
son/transposase ratio is fixed, conferring less flexibility to the system. Second, the plasmid
backbone could be integrated as well as, third, the transposase gene. Even if the pseudo-
transposon/transposase ratio is fixed, working on promoters has brought flexibility. Indeed,
Mikkelsen et al. [35] compared the efficiency of their helper-independent SB vector depending
on 11 different promoters used for driving the transposase gene and they observed the OPI
phenomenon with the strongest promoter.
In the “trans” configuration, two molecules are used, one carrying the gene of interest and one
bringing the transposase either in DNA, RNA, or protein forms. The trans configuration offers
naturally more flexibility than the cis one. On the one hand, this approach gives the advantage
to modulate the molecular ratio between the transposase and the pseudo-transposon. On the
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other hand, this approach gives the possibility to introduce several independent pseudo-
transposons [36] in their inducible systems. Only one constraint has been detailed: transpo‐
sases are able to catalyze integration more efficiently with a circular donor plasmid than with
a linear one [37].








Conventional cis architecture High [47,48]












Conventional trans architecture: two separate plasmids Low [48,50]
Pseudo-transposon + transposase as mRNA Not [51–54]
Pseudo-transposon + transposase as protein Not [55–57]
Table 1. Different configurations to deliver transposase and pseudo-transposon and their consequences. Transposase
molecules are in green whatever is the molecule type. Pseudo-transposon molecule is drawned in blue. GOI, gene of
interest; p(A), polyadenylation signal; Prom, promoter; Tnpase, transposase; ITR, Inverted terminal repeats.
2.2.2. Risks and solutions associated to each strategy
2.2.2.1. Risk of linearized backbone integration
After excision of the gene of interest, the backbone thereby linearized is more prone to be
integrated by a nontransposition process [38], whatever the cis or trans configuration used.
This undesired integration exposes the problem of the presence of bacterial sequence such as
resistance gene or bacterial replication origin. This has been correlated with the amount of
transfected transposase [38] and with the size of the transgene [39]. To avoid this, Wilson’s
team suggested to use a suicide gene in the plasmid backbone, [40] or to select cells expressing
green fluorescent protein (GFP) present in the backbone donor plasmid [38]. Other authors
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suggested using DNA minicircles [41]. Interestingly, they also observed an increased efficacy
with DNA minicircles compared to standard plasmid for the same transgene size in several
cell lines. However, keeping only the pseudo-transposon as linearized donor plasmid showed
no efficacy with SB transposase [42] and a low one with the PB transposase [37].
2.2.2.2. Risk of transposase gene integration
The presence of the transposase gene within the plasmid generates risk of its own integration
and per se a risk of sustained transposase expression. The consequence could be saltatory
remobilization of the integrated transgene [43]. To limit the effect of sustained transposase
expression, a self-inactivated transposase gene has been obtained by including either the
promoter [44,45] or the polyadenylation signal [46] between the ITRs (Table 1). Indeed, in
primary human T cells, authors identified an active SB transposase ORF only in one clone out
of 94, but a bulk analysis showed up to 0.047 transposase copy integrated per cell [50]. This
still has not been evaluated for the PB and Tol2 transposases. Nevertheless, it is possible to
completely abolish its integration by introducing transposase under mRNA or protein form
(Table 1) [51]. mRNA or protein forms allow a one-shot transposition process, thanks to the
time-restricted transposase expression.
For example, mRNA transposase expression peaked at 18 h after transfection [58]. Galla et al.
[52] demonstrated less cell mortality with the mRNA transposase than an integrative form.
Bire et al. [51] showed that the mRNA transposase gave less double-stranded break formation
and less copy transgene integration. Moreover, no integrations of the transposase mRNA have
been highlighted [51]. These considerations have been confirmed in vivo [53], as detailed in the
end of this chapter.
Using the protein transposase offers also a short window of expression. Cai et al. [55] recently
used the transposase protein associated with viral polyprotein. They observed a high number
of transgene expressing cells, with a few number of integrated transgene copies per genome.
Aiming to limit viral particle uses, recombinant transposase protein was fused with the cell
penetrating peptide (CPP) [56] or transposase was delivered with a free CPP [57]. For now, no
in vivo evaluations have been found in the bibliographic database.
3. Editing the genome: the final step after a long journey through the cell
Genome editing includes all methods aimed to modify the genome by introducing new DNA
sequences or by correcting existing genomic sequences. The journey begins with the ability to
enter into the cell, evade the immune response, and, after crossing the nuclear barrier, integrate
the gene of interest into the DNA genome.
3.1. Cross the cellular membrane and escape immune response
As free DNA delivery did not show efficient results, both transposase and pseudo-transposon
need to be driven into the cell using different gene delivery strategies, either using a carrier
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(viral particles or chemical agent) or using a physical method. According to the method
selected, it is important to consider all parameters of cellular defense against the entry of the
foreign DNA.
3.1.1. Viral hybrid systems
The viral-transposon hybrid systems take advantage of the natural properties of viral proteins
to enter into the cell. For example, as early as 2006, a hybrid HSV amplicon-SB transposase
vector was used in a central nervous system development study [59]. Since that time, several
studies have been developed on hybrid transposase systems (reviewed in Refs. [60,61]) that
use adenovirus [62–64], adeno-associated virus [65], baculovirus [66], or nonintegrative
lentivirus [67,68] particles.
3.1.2. Chemical agents
Chemical agents have been developed with the aim of condensating DNA and thereby
avoiding any viral derived systems. However, it turns out to be more controversial than
expected with respect to the immune escape [69]. Indeed, these nanovehicles enter into the cell
essentially via the endosomal pathway [70,71] and therefore expose foreign DNA to the
endosomal Toll-like receptors. Among all available chemical carriers, the polyethylenimine
(PEI) polymers appear to be the most used in transposon systems. Indeed, the PEI improve
endosomal escape through the “proton sponge” mechanism. For example, in 2009, Kang et al.
[72] used the PB transposase-based system with the PEI as a transfection reagent for ovarian
cancer treatment in a mouse model. Further examples have been realized both in vitro [73] and
in vivo [36,74].
3.1.3. Physical gene transfer
Finally, plasmid DNA could be driven by physical methods. In this case, the plasmid traffic
does not go through the endosome and thereby escapes Toll receptors. One such method,
electroporation, turned out to be highly efficient to transfect otherwise hard to transfect cells
such as dendritic cells and human hematopoietic or embryonic cells [75–77]. Depending on
the cell type used, the results may be controversial. Ley et al. [73] compared transposition
efficiency in PEI-transfected versus electroporated mesoangioblasts and were not able to
obtain efficient long-term expression in muscle after in vivo electroporation.
Other physicals methods have therefore been developed. For example, ultrasound targeted
microbubble destruction (UTMD) results in pore formation on the cell membrane after
ultrasonic waves application. Recently, two in vivo studies have been carried out with clinical
perspectives [78,79]. In parallel to UTMD, the hydrodynamic (HD) injection has been applied
to transfer the clotting factor VIII [80]. However, they are proinflammatory consequences
inducing a lack of transgene expression. To circumvent this drawback, Doherty et al. [81]
suggested to induce transient transgene repression, thereby preventing the priming of
transgene-specific T cells.
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3.2. Cross the nuclear barrier and transgene integration
3.2.1. The transposase is driven to the nucleus
For an efficient transposition, the transposase needs to be localized into the nucleus at the same
time as the pseudo-transposon DNA.
The transposases contain a nuclear localization signal, driving them to the nucleus [82]. An
engineered PB transposase have been developed for increasing its localization within the
nucleoli by adding a nucleolus-predominant (NP) signal peptide from HIV-1 TAT protein [83].
With this NP-mPB, a three- to fourfold increase in PB transposition rate, in both murine and
human cells, was observed.
From the pseudo-transposon point of view, its nuclear targeting is also essential. Thus, DNA
nuclear targeting sequences (DTS) might be added to the plasmid backbone. These DTS consist,
for example, to a 72-bp sequence from the SV40 enhancer and act as a sequence driver [84].
3.2.2. Integration profile of the gene of interest
All transposon systems have less integration bias than viruses, as previously described [85–
88]. However, it is important to note that there are some differences within transposon systems
[89]. The SB transposase is known to allow the more random integration [90], with approxi‐
mately 35% into RefSeq sequences. It has been notified that the SB transposition has an affinity
for the heterochromatin topology [91]. In contrast, the Tol2 and PB transposases are not
considered to allow random integration. Indeed, the PB transposase shows a bias towards
integration of the transgene into CpG islands and transcriptional start site, with approximately
49% into RefSeq sequences [16,27], and the Tol2 transposase presents a strong bias for the
intergenic regions [92].
Interestingly, this global integration profile could be affected by various parameters, such as
the transposase variant [93] or the cell type [94].
In addition, it is important to note that, for now, studies have been essentially established in
in vitro models and no predictions could be drawn regarding the in vivo integration profile.
Indeed, after in vivo UTMD transfection, the pseudo-transposon showed a significant bias of
transgene integration into chromosome 14 [49], but no bias was observed in their in vitro
control.
4. Side effect of the transgene integration system
The newly integrated foreign DNA is considered as an invader by the cell. This leads to
postintegrative transgene silencing. Conversly, the transgene copy might also influence
surrounding sequences according to the integration site. To conter these mutual side-effects
numerous strategies have been developed.
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4.1. Communication mechanisms between the transgene and the genome
During their evolution, transposons have been made extinct by at least chromatin condensa‐
tion and by RNA interference (RNAi) induction.
The transcriptional regulation includes DNA CpG methylation and histone modifications. It
has been confirmed that the transgene expression could be restored by a demethylating agent
such as 5-aza-2’-deoxycytidine or by a histone deacetylase inhibitor such as trichostatin A [95].
However, it is easier to avoid the induction of upstream gene silencing. To this end, working
with a methylated pseudo-transposon plasmid unlike an unmethylated one showed more
transposition rate with the SB transposase [96]. Curiously, when the SB, PB, and Tol2 trans‐
posase systems are directly compared, the integrated transgene is less silenced if integrated
by the PB transposase [97].
The role of RNAi in posttranscriptional silencing of exogenous DNA transposons remains
unclear. One study demonstrated that, in the absence of an efficient cellular RNAi system, by
establishing p19 protein knockdown cells, the number of colonies is increased [98]. Nonethe‐
less, the mechanism is still not elucidated.
Besides the host-to-transgene effect, a transgene-to-host effect, driving perturbations in
sequences surrounding the transgene by DNA methylation modulation, has been highlighted
[99]. A further study investigated the expression levels of host genes neighboring the SB
transposon and underlined variations depending on the chromosomal location of the trans‐
gene [100]. Therefore, solutions allowing a complete isolation of the transgene should be
developed.
4.2. Overcoming the host regulation for a sustained expression
In gene correction, maintaining the expression level of the transgene and limiting host genome
perturbations are crucial for having an efficient therapeutic effect.
4.2.1. Matrix attachment region (MAR)
The human MAR elements are natural elements of the eukaryotic genome, which mediate the
structural organization of the chromatin domains. When included in a transposon plasmid,
they do not affect the number of transposed transgene copies but rather increase the transgene
expression per integrated copy [101]. Moreover, when the MAR element is included in the
transposase vector, an increased transposition efficacy has been observed [102].
4.2.2. Insulators
Insulators are short DNA sequences naturally present in the genome and act as genetic
boundary elements. In a recent study, four different insulators (cHS4, D4Z4, CTCF, and CTF/
NF1) were compared and showed that D4Z4 and CTF/NF1 had insulator functions when
combined with transposition [51]. The protective effect of the cHS4 insulator has been
demonstrated by a strong diminution of the activation of a nearby promoter [103] and by a
prolonged fluorescent marker expression [104,105]. Some equivalent studies corroborated this
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role in clinically relevant cells as well as primary hematopoietic CD34+ cells [106]. Moreover,
cHS4 insulators abolished the RNAi pathway effects regulating transposon-derived transgene
expression by epigenetic silencing [98]. Nevertheless, for an optimal boundarie effect of
insulators, it is necessary to consider the model used. Indeed, the size of the pseudo-transposon
increased by the insulator or steric hindrance of transposase action [103] could also influence
the transgene expression..
5. Going further
For many years, researchers have provided elements for a better understanding of their
mechanism and have given solutions for the optimal use of these systems. Here, we recall
promising leads for further work in this area: targeting a specific site within the genome and
targeting a specific tissue at the body scale.
5.1. Targeting a specific site within the genome
Replacing a defective gene or introducing a gene of interest into a completely safe, predeter‐
mined, specific genomic site is the ideal approach for gene correction. This potential locus
could be defined by numerous criteria determined by its position from gene, miRNA, tran‐
scription unit, or ultraconserved region. All of these aspects have been recently reviewed [107].
5.1.1. Transposon targeting strategies
The SB, PB, and Tol2 transposases have short integration target sites: TA, TTAA, and 8-bp
sequences, respectively. Thus, transposon-derived systems should be optimized by combining
the transposase to a system able to target a specific DNA sequence, such as a DNA-binding
domain (DBD). The first strategy uses a fusion protein containing both the transposase and a
DBD. In the second method, a fusion protein is constructed between a DBD and a protein,
which is able to specifically recruit the transposase. To date, only one protein is known to be
able to interact with the SB transposase, which is named N-57 [108]. Finally, another solution
is based on a fusion protein between two DBD, one recognizing a genomic sequence and one
specific to a sequence inserted within the pseudo-transposon plasmid. Few parameters of this
third approach have been explored in a mammalian model [108]. Considerations of these three
strategies have been recently reviewed [109], and we herein detail only chimeric transposases.
The proof-of-concept has been demonstrated by studying intraplasmic integration using the
PB transposase fused to the Gal4 domain [110]. However, the system revealed to be more
restrictive than expected both in the conservation of the transposition activity and the ability
to restrict integration in the targeted locus. Therefore, the transposition activity might be
affected by the DBD fusion. Indeed, the DBD Gal4 (a zinc finger domain, ZF) has been tested
in fusion to the Tol2, SB11, and PB transposases. The number of chromosomal integrations of
the transposon is abolished with Gal4-Tol2 and Gal4-SB11, but no loss of efficiency was
observed for the Gal4-PB transposase [111]. Some studies have been carry out to analyze the
parameters of this loss of activity, such as the sequence surrounding the targeted site [108], the
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orientation of the fusion [112], or the choice of the linker [113]. The DBD type has also been
evaluated in their ability to avoid off-target integration. With the Gal4-PB transposase,
transposition occurred at 23% within 0.8 kb of Gal4 site compared to 5% for the native
transposase [114]. However, for improvement of the targeting, artificial ZFs have been created
by assembling six ZF domains to create a polydactyl protein capable of targeting a unique
sequence of 18 bp [115]. For example, the sequence targeting with these artificial ZF allowed
44.3% of integration events near the CHK2-ZF site [116]. Comparatively, when the Sp1 ZF is
fused with the PB transposase, which preferentially binds the CG-rich motif, the integration
increased near the CpG islands (25.7% versus 10.5% with the native PB transposase) but
without modification regarding the integration into the RefSeq genes [117].
5.1.2. Other systems allowing a targeting integration
In 2011, the discovery of the CRISPR/Cas9 system revolutionized the gene transfer because of
its ability to drive the transgene in its physiological site, but no studies directly compared the
efficiency of both transposon and CRISPR/Cas9-based systems. It has been supposed that this
system arises from casposon in the evolutionary tree. Casposons are mobile cryptic sequences
present in Achaea and bacteria, and two independent studies described this superfamily of
mobile elements by linking transposon and CRISPR/Cas systems [118,119].
Recently, a combinatory approach was developed, in which the correction is realized gene by
gene (CRISPR/Cas9 role) and temporarily needed sequences are removed from the genome
(transposase role). This method has been applied for gene correction of β-thalassemia [120]
and to create iPSC with deletion into the CCR5 gene [121].
5.2. Targeting a specific tissue at the organism scale
For in vivo application of gene correction, it is important to express the transgene of interest
only in the organ, tissue, or cell types in which the transgene expression is required. The design
of the transgene vector is essential and might contain specific elements such as tissue-specific
promoter or regulatory sequences. The second option is to deliver the system only in the
specific cells.
5.2.1. Design of the transgene vector for in vivo applications
In the ideal gene transfer, the transgene is expressed in the same conditions, as it is in phys‐
iological conditions. Indeed, overexpression of the transgene or expression in a nontarget cell
could improve cytotoxicity, induce its clearance by the immune system, and increase its gene
silencing (reviewed in Ref. [122]). With this aim, vectors have been designed in such a way as
promoters or regulatory sequences are chosen for restricting the expression of the gene of
interest only in the cells of interest. Tissue-specific promoters control gene expression in a
tissue-dependent manner or according to the development stage of the cells. In plasmid design,
several approaches are available such as using a promoter regulating an endogenous gene
expressed in one type of cell (minimal promoter) or combining numerous enhancers to a
minimal promoter.
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In the first case, the transposon is under a native promoter. For example, endothelin-1 [123]
allows a decreased GFP expression in a nonendothelial cell line while maintaining the
expression level in endothelial cell lines. When the targeted cell type is the final point of a
differentiation lineage, it seems essential to have the expression of the therapeutic protein only
in the differentiated state, such as promoters capable of restricting β-globin expression in
differentiated erythroid cells from transfected proerythroid cells [124]. In cancer therapy, a
study based on the SB transposition showed that the HSV-TK transgene driven by a telomerase
reverse transcriptase promoter increased death rate in cancer cell lines compared to fibroblast
cell lines [125].
The second approach is based on constructions containing a minimal promoter with specific
enhancers. For example, the SB transposon system has been used for the introduction of the
telomerase gene driven by a combination of the transthyretin (TTR) gene promoter/enhancer,
the human alcohol dehydrogenase gene promoter, and the SV40 enhancer [126]. The authors
observed an induced transcriptional activity only in hepatocytes. In an in vivo study, the
authors developed a TTR minimal promoter coupled to a hepatocyte-specific cis-regulatory
module, driving the clotting factor IX for correction of hemophilia B [127]. This promoter has
also been combined with a PB transposon-mediated gene transfer and confirmed the high
efficiency of the transgene construct [128].
5.2.2. Limiting the ectopic integrations by tissue targeting
For improvement of tissue targeting, two major routes have been developed, either adminis‐
tration of ex vivo premodified cells of interest or direct delivery of the integrative system,
containing the transgene, to the whole organism.
5.2.2.1. Administration route for ex vivo modified cells
The delivery of premodified cells to a patient was extensively carried out in adoptive cell
transfer of immune cells expressing an artificial T-cell receptor (TCR) designed to target an
antigen. Briefly, T cells are removed from a patient and transformed to express the artificial
TCR (also named chimeric antigen receptor or CAR). After amplification, modified T cells are
intravenously readministrated to the organism. In the field of transposon technology, this
approach has been used in several applications. For example, a human epidermal growth
factor receptor 2-specific CAR was introduced into cytotoxic T cells, thanks to the PB trans‐
posase [129]. More recently, T lymphocytes were modified to express the CD19-CAR trans‐
gene, and after 7 days of coculture, CAR T cells eradicated all CD19+ tumor cells in vitro [130].
In lower proportions, the Tol2 transposase has also been used for the integration of a CD19-
CAR into T cells [131]. However, production of CD19-CAR T cells usually uses SB transposase
and clinical trials are currently under investigation [132]. The authors detailed their protocol
for manufacturing clinical-grade CD19-specific T cells [76].
It is also possible to reimplant modified cells in situ after their encapsulation. In this aim, Fjord-
Larsen et al. [133] developed a model in which a new clinical-grade cell line expresses a high
level of neural growth factor after striatum implantation.
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The administration of already modified cells increases the security of the transfer system.
However, applications are, for now, restricted to cells easy to collect and reimplant to a patient.
For less accessible tissue or organs, targeting methods are more often driven by a direct
administration of the transgene.
5.2.2.2. Administration route for transposon DNA system
The administration of the therapeutic gene, associated with the transposase, needs a delivery
method able to drive them into the organ or tissue of interest. To this end, two strategies have
been developed. The first one takes advantages of specific administration route properties,
whereas the second one uses vehicles expressing receptors capable of specific recognition of
the targeting tissue.
It has been demonstrated that all gene delivery methods do not present an equal distribution
in the different organs. For example, the HD injection is known to target the liver at 95%, as
detailed by Bell et al. [134]. In agreement, Herweijer and Wolff [135] showed that transgene
expression was also found in others organs such as the heart, spleen, and kidneys at levels
approximately 100-fold lower than in the liver. This liver targeting way has been applied in
gene correction, and in 2007, Aronovich et al. showed a model of correction of mucopolysac‐
charidosis mice by SB-mediated transgene α-L-iduridase (IDUA) transposition [136]. They
mentioned a persistent expression of IDUA in plasma for almost 10 weeks after injection. In
cancer therapy, liver metastasis of colorectal cancer was reduced after antiangiogenic genes
were integrated by the SB transposase [137].
As a complement, the DNA transposon could also been administrated after complexation to
a targeting vehicle. After an intravenous administration, Kren et al. [47] highlighted a hepa‐
tocyte-specific integration of the transgene when condensated with coated nanocapsules.
Comparatively, the transgene complexed to the PEI showed an expression in the lung, not
observed after HD injection [138]. More specifically, within the lung, the polyplexes are
addressed into pneumocytes and no transgene expression was detected within the conducting
airways [139].
Coupling specific administration route and nanocapsules is the future way. In this aim, the
UTMD gene delivery method allows mediating the site-specific delivery of transposons.
Briefly, the transgene is intravenously injected and cell penetration occurs at the targeted organ
by acoustic cavitation [49]. This approach has been used for the transposition of the Nkx2.2
transcriptional factor to the pancreas by the PB system [78] or for the transposition of the
thymosine β4 gene, or the glucagon-like peptide-1 one, to the heart [79,140].
In gene correction, targeting the tissue of interest is essential for reflecting physiological
conditions. Compared to viral transduction, the transposon systems are more customizable
and numerous possibilities are available for users. Depending on the tissue to target, it is
possible to play at the same time on the promoter, the administration route, and the presence
of targeting molecules.
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6. Therapy applications of transposase tools
Some technological aspects previously discussed offer a suitable transposon toolbox to gene
correction. Transposon-based systems allow first the transgene integration in a large range of
clinically relevant target cells, including hematopoietic stem cells [141], mesenchymal stromal
cells [142], iPSC [143], and lymphoid T cells [131]. Transposon-mediated correction could
therefore be used in a large-scale application, such as treatment of inherited disorders, cancer,
and tissue degeneration (Table 2).




Hemophilia A FVIII SB/PB Hemophilic A mice [47,80,144–146]
Hemophilia B FIX SB/PB Hemophilic B
mice or dogs
[42,62,128,147]
Huntington’s disease siRNA-htt SB Human cell lines [148]
Duchene muscular
dystrophy
Dystrophin PB Dog dystrophic
mesoangioblast
[24]
Tyrosinemia type I Fah SB FAH-deficient mice [149–151]
Sickle cell disease HO-1 or IHK SB Mice [152,153]
Mucopolysaccharidosis type I
(MPS I)
hIDUA or hGUSB SB MPS I NOD/SCID mice [136,154,155]
α-Antitrypsin deficiency hAAT PB Mice and iPSC [93,156]
Fanconi anemia type C FA-C SB Human lymphoblastoid cells [157]
Crigler-Najjar syndrome type 1 hUGT1A1 SB Hepa1 cell line and gunn rats [158]
Junctional epidermolysis
bullosa (JEB)






eGFP PB Mice [160]
Regenerative medicine
iPSC generation SOX2, OCT4, KLF4,
and c-MYC
PB Fibroblasts, melanoma cells,
HDDPC
[32,143,161–164]
Diabetes Nkx2.2 or insulin PB/SB STZ-rat pancreas [78,165]
Retinal degeneration PEDF SB IPE and RPE cells [166]
Acute myocardial infraction TB4 or GLP1 PB Rat heart [79,140]
Cancerology
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sFlt-1 or statin-AE SB Tumor engrafts in mice [66,137,167]
Cervical cancer HSV-tk PB Cervical cancer
xenografts
[72]
Ovarian adenocarcinoma HSV-tk PB Cell line [168]
Melanoma TRAIL and IFNγ PB ADSC [169]















Pulmonary hypertension eNOS SB Monocrotaline-induced
pulmonary hypertension rats
[182]
Acute cellular injury hTERT SB Primary hepatocytes [126]
Unilateral ureteral
obstruction
IGF-1R PB Mice [183]
Tnpase, transposase ; ADSC, adipose-derived mesenchymal stem cells; eGFP, enhanced GFP; eNOS, endothelial nitric
oxide synthase; FA-C, Fanconi anemia complementation group C; Fah, fumaryl-acetoacetate hydrolase; FVIII, clotting
factor, factor VIII; hAAT, human α1-antitrypsin; HDDPC, primary human deciduous tooth dental pulp cells; HER2,
human epidermal growth factor receptor 2; hGUSB, β-glucoronidase; hIDO, human indoleamine-2,3-dioxygenase;
hIDUA, human α-L-iduronidase; HO-1, heme oxygenase-1; HSV-tk, herpes simplex virus thymidine kinase; hTERT,
human telomerase reverse transcriptase; htt, huntingtin; hUGT1A1, human uridine diphosphoglucuronate
glucuronosyltransferase 1A1; IFNγ, interferon γ; IGF-1R, insulin-like growth factor-1 receptor; IHK, antisickling
globin; IL-11, interleukin-11; IPE, iris epithelial cells; KLF4, Krüppel-like factor 4; LAMB3, laminin B3 subunit of
laminin 5; Nkx2.2, NK-type homeodomain transcription factor; OCT4, octamer-binding transcription factor 4; PEDF,
pigment epithelium-derived factor; RPE, pigment epithelial cells; sFlt-1, soluble fms-like tyrosine kinase-1; SOX2, SRY
(sex-determining region Y) box 2; statin-AE, angiostatin-endostatin fusion gene; STZ, streptozotocin; TB4, thymosin β4;
Tnpase, transposase; TRAIL, TNF-related apoptosis-inducing ligand.
Table 2. Application fields of transposon-based gene correction.
7. Conclusion
Transposons have naturally drawn genomes since the first forms of life. Scientists have taken
advantage of their properties with the aim of constantly updating the safety of this nonviral
tool for gene transfer. With the other integrative systems derived from casposons, such as
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CRISPR/Cas9, we dispose of complementary tools for reshaping the genome. Latest discov‐
eries have open new horizons, but a long road is still ahead.
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